The estimated Net Worth of Lourdes Weltzien is at least $4.18 Million dollars as of 15 February 2022. Lourdes Weltzien owns over 20,000 units of Meridian Bioscience stock worth over $3,500,541 and over the last 7 years he sold VIVO stock worth over $0. In addition, he makes $675,550 as Executive Vice President - Life Science at Meridian Bioscience.
Lourdes has made over 1 trades of the Meridian Bioscience stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of VIVO stock worth $290,400 on 15 February 2022.
The largest trade he's ever made was exercising 20,000 units of Meridian Bioscience stock on 15 February 2022 worth over $290,400. On average, Lourdes trades about 1,250 units every 0 days since 2018. As of 15 February 2022 he still owns at least 103,048 units of Meridian Bioscience stock.
You can see the complete history of Lourdes Weltzien stock trades at the bottom of the page.
Dr. Lourdes Weltzien serves as Executive Vice President - Life Science of the Company. Dr. Weltzien held various executive and management positions with Sigma-Aldrich Corporation (now Millipore-Sigma) since 1994.
As the Executive Vice President - Life Science of Meridian Bioscience, the total compensation of Lourdes Weltzien at Meridian Bioscience is $675,550. There are 2 executives at Meridian Bioscience getting paid more, with John P. Kenny having the highest compensation of $1,508,705.
Lourdes Weltzien is 54, he's been the Executive Vice President - Life Science of Meridian Bioscience since 2018. There are 9 older and 3 younger executives at Meridian Bioscience. The oldest executive at Meridian Bioscience Inc. is David Phillips, 81, who is the Independent Chairman of the Board.
Lourdes's mailing address filed with the SEC is 3471 RIVER HILLS DRIVE, , CINCINNATI, OH, 45244.
Over the last 22 years, insiders at Meridian Bioscience have traded over $8,089,514 worth of Meridian Bioscience stock and bought 228,244 units worth $3,053,655 . The most active insiders traders include Richard Eberly, John P. Kenny, and John A Kraeutler. On average, Meridian Bioscience executives and independent directors trade stock every 41 days with the average trade being worth of $424,761. The most recent stock trade was executed by James M. Anderson on 6 January 2023, trading 8,500 units of VIVO stock currently worth $173,230.
Meridian Bioscience Inc. is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.The company is dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, Meridian provides critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, Meridian provides diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. The company builds relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian Bioscience executives and other stock owners filed with the SEC include: